251
|
Fornoni A, Pileggi A, Molano RD, Sanabria NY, Tejada T, Gonzalez-Quintana J, Ichii H, Inverardi L, Ricordi C, Pastori RL. Inhibition of c-jun N terminal kinase (JNK) improves functional beta cell mass in human islets and leads to AKT and glycogen synthase kinase-3 (GSK-3) phosphorylation. Diabetologia 2008; 51:298-308. [PMID: 18066521 DOI: 10.1007/s00125-007-0889-4] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/12/2007] [Accepted: 10/26/2007] [Indexed: 12/31/2022]
Abstract
AIMS/HYPOTHESIS Activation of c-jun N-terminal kinase (JNK) has been described in islet isolation and engraftment, making JNK a key target in islet transplantation. The objective of this study was to investigate if JNK inhibition with a cell-permeable TAT peptide inhibitor (L-JNKI) protects functional beta cell mass in human islets and affects AKT and its substrates in islet cells. METHODS The effect of L-JNKI (10 micromol/l) on islet count, mitochondrial membrane potential, glucose-stimulated insulin release and phosphorylation of both AKT and its substrates, as well as on reversal of diabetes in immunodeficient diabetic Nu/Nu mice was studied. RESULTS In vitro, L-JNKI reduced the islet loss in culture and protected from cell death caused by acute cytokine exposure. In vivo, treatment of freshly isolated human islets and diabetic Nu/Nu mice recipients of such islets resulted in improved functional beta cell mass. We showed that L-JNKI activates AKT and downregulates glycogen synthase kinase-3 beta (GSK-3B) in human islets exposed to cytokines, while other AKT substrates were unaffected, suggesting that a specific AKT/GSK-3B regulation by L-JNKI may represent one of its mechanisms of cytoprotection. CONCLUSIONS/INTERPRETATION In conclusion, we have demonstrated that targeting JNK in human pancreatic islets results in improved functional beta cell mass and in the regulation of AKT/GSK3B activity.
Collapse
Affiliation(s)
- A Fornoni
- Diabetes Research Institute, University of Miami Miller School of Medicine, 1450 NW 10th Avenue, Miami, FL 33136, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
252
|
Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med 2008; 14:144-53. [PMID: 18223655 DOI: 10.1038/nm1717] [Citation(s) in RCA: 246] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2007] [Accepted: 12/20/2007] [Indexed: 12/25/2022]
Abstract
The proapoptotic BCL-2 family member BAD resides in a glucokinase-containing complex that regulates glucose-driven mitochondrial respiration. Here, we present genetic evidence of a physiologic role for BAD in glucose-stimulated insulin secretion by beta cells. This novel function of BAD is specifically dependent upon the phosphorylation of its BH3 sequence, previously defined as an essential death domain. We highlight the pharmacologic relevance of phosphorylated BAD BH3 by using cell-permeable, hydrocarbon-stapled BAD BH3 helices that target glucokinase, restore glucose-driven mitochondrial respiration and correct the insulin secretory response in Bad-deficient islets. Our studies uncover an alternative target and function for the BAD BH3 domain and emphasize the therapeutic potential of phosphorylated BAD BH3 mimetics in selectively restoring beta cell function. Furthermore, we show that BAD regulates the physiologic adaptation of beta cell mass during high-fat feeding. Our findings provide genetic proof of the bifunctional activities of BAD in both beta cell survival and insulin secretion.
Collapse
|
253
|
Buitenhuis M, Verhagen LP, van Deutekom HWM, Castor A, Verploegen S, Koenderman L, Jacobsen SEW, Coffer PJ. Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis. Blood 2008; 111:112-21. [PMID: 17890457 DOI: 10.1182/blood-2006-07-037572] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Hematopoiesis is a highly regulated process resulting in the formation of all blood lineages. Aberrant regulation of phosphatidylinositol-3-kinase (PI3K) signaling has been observed in hematopoietic malignancies, suggesting that regulated PI3K signaling is critical for regulation of blood cell production. An ex vivo differentiation system was used to investigate the role of PI3K and its downstream effector, protein kinase B (PKB/c-akt) in myelopoiesis. PI3K activity was essential for hematopoietic progenitor survival. High PKB activity was found to promote neutrophil and monocyte development, while, conversely, reduction of PKB activity was required to induce optimal eosinophil differentiation. In addition, transplantation of β2-microglobulin (−/−) NOD/SCID mice with CD34+ cells ectopically expressing constitutively active PKB resulted in enhanced neutrophil and monocyte development, whereas ectopic expression of dominant-negative PKB induced eosinophil development in vivo. Inhibitory phosphorylation of C/EBPα on Thr222/226 was abrogated upon PKB activation in hematopoietic progenitors. Ectopic expression of a nonphosphorylatable C/EBPα mutant inhibited eosinophil differentiation ex vivo, whereas neutrophil development was induced, demonstrating the importance of PKB-mediated C/EBPα phosphorylation in regulation of granulopoiesis. These results identify an important novel role for PKB in regulation of cell fate choices during hematopoietic lineage commitment.
Collapse
Affiliation(s)
- Miranda Buitenhuis
- Molecular Immunology Lab, Department of Immunology, University Medical Center, Utrecht, the Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
254
|
Quigley M, Huang X, Yang Y. Extent of stimulation controls the formation of memory CD8 T cells. THE JOURNAL OF IMMUNOLOGY 2007; 179:5768-77. [PMID: 17947649 DOI: 10.4049/jimmunol.179.9.5768] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Only a small fraction of effector CD8 T cells survives to become long-lived memory cells, whereas the majority of them die after an acute infection. What controls the formation of memory CD8 T cells remains mostly unknown. In this study, we showed CD8 T cells primed earlier during vaccinia viral infection received stronger stimulation, divided more extensively, and survived better than those primed later, leading to generation of a larger memory pool. Despite differentiation into effectors, the late-primed CD8 T cells lacked full cell division, displayed increased apoptosis, and failed to develop into memory cells, suggesting that the extent of stimulation influences the survival of effector CD8 T cells. We further demonstrated that the extent of stimulation, which included both the duration and the levels of antigenic stimulation/costimulation, during priming determined the formation of memory CD8 T cells via controlling the extent of Akt activation, and functional suppression of Akt led to defective CD8 memory formation in vivo. Collectively, our data suggest that the extent of stimulation controls CD8 memory formation via activation of Akt and may provide important insights into the design of effective vaccines.
Collapse
Affiliation(s)
- Michael Quigley
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
| | | | | |
Collapse
|
255
|
Grempler R, Leicht S, Kischel I, Eickelmann P, Redemann N. Inhibition of SH2-domain containing inositol phosphatase 2 (SHIP2) in insulin producing INS1E cells improves insulin signal transduction and induces proliferation. FEBS Lett 2007; 581:5885-90. [DOI: 10.1016/j.febslet.2007.11.066] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2007] [Revised: 10/25/2007] [Accepted: 11/20/2007] [Indexed: 12/31/2022]
|
256
|
Yano T, Liu Z, Donovan J, Thomas MK, Habener JF. Stromal cell derived factor-1 (SDF-1)/CXCL12 attenuates diabetes in mice and promotes pancreatic beta-cell survival by activation of the prosurvival kinase Akt. Diabetes 2007; 56:2946-57. [PMID: 17878289 DOI: 10.2337/db07-0291] [Citation(s) in RCA: 108] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
OBJECTIVE Diabetes is caused by a deficiency of pancreatic beta-cells that produce insulin. Approaches to enhance beta-cell mass by increasing proliferation and survival are desirable. We determined whether stromal cell-derived factor (SDF)-1/CXCL12 and its receptor, CX chemokine receptor (CXCR)4, are important for the survival of beta-cells. RESEARCH DESIGN AND METHODS Mouse pancreata and clonal beta-cells were examined for expression of SDF-1 and CXCR4, activation of AKT and downstream signaling pathways by SDF-1, and protection against apoptosis and diabetes induced by streptozotocin (STZ). RESULTS CXCR4 is expressed in beta-cells, and SDF-1 is expressed in microvascular endothelial cells within the islets and in surrounding interstitial stromal tissue. Transgenic mice overexpressing SDF-1 within their beta-cells (RIP-SDF-1 mice) are resistant to STZ-induced beta-cell apoptosis and diabetes. In MIN6 beta-cells, a CXCR4 antagonist (AMD3100) induces apoptosis, increases reactive oxygen species, decreases expression levels of the anti-apoptotic protein Bcl-2, and reduces phosphorylation of the proapoptotic protein Bad. Active phosphorylated prosurvival kinase Akt is increased both in the beta-cells of RIP-SDF-1 mice and in INS-1 cells treated with SDF-1 and sensitive to AMD3100. Inhibition of AKT expression by small interfering RNA attenuates the ameliorative effects of SDF-1 on caspase-dependent apoptosis induced by thapsigargin or glucose deprivation in INS-1 beta-cells. Specific inhibition of Akt activation by a soluble inhibitor (SH-5) reverses the anti-apoptotic effects of SDF-1 in INS-1 cells and mouse islets. CONCLUSIONS SDF-1 promotes pancreatic beta-cell survival via activation of Akt, suggesting that SDF-1 agonists may prove beneficial for treatment of diabetes.
Collapse
Affiliation(s)
- Tatsuya Yano
- Laboratory of Molecular Endocrinology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
| | | | | | | | | |
Collapse
|
257
|
Morioka T, Asilmaz E, Hu J, Dishinger JF, Kurpad AJ, Elias CF, Li H, Elmquist JK, Kennedy RT, Kulkarni RN. Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice. J Clin Invest 2007; 117:2860-8. [PMID: 17909627 PMCID: PMC1994606 DOI: 10.1172/jci30910] [Citation(s) in RCA: 169] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2006] [Accepted: 07/06/2007] [Indexed: 12/13/2022] Open
Abstract
Obesity is characterized by hyperinsulinemia, hyperleptinemia, and an increase in islet volume. While the mechanisms that hasten the onset of diabetes in obese individuals are not known, it is possible that the adipose-derived hormone leptin plays a role. In addition to its central actions, leptin exerts biological effects by acting in peripheral tissues including the endocrine pancreas. To explore the impact of disrupting leptin signaling in the pancreas on beta cell growth and/or function, we created pancreas-specific leptin receptor (ObR) KOs using mice expressing Cre recombinase under the control of the pancreatic and duodenal homeobox 1 (Pdx1) promoter. The KOs exhibited improved glucose tolerance due to enhanced early-phase insulin secretion, and a greater beta cell mass secondary to increased beta cell size and enhanced expression and phosphorylation of p70S6K. Similar effects on p70S6K were observed in MIN6 beta cells with knockdown of the ObR gene, suggesting crosstalk between leptin and insulin signaling pathways. Surprisingly, challenging the KOs with a high-fat diet led to attenuated acute insulin secretory response to glucose, poor compensatory islet growth, and glucose intolerance. Together, these data provide direct genetic evidence, from a unique mouse model lacking ObRs only in the pancreas, for a critical role for leptin signaling in islet biology and suggest that altered leptin action in islets is one factor that contributes to obesity-associated diabetes.
Collapse
Affiliation(s)
- Tomoaki Morioka
- Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
Laboratory of Molecular Genetics, The Rockefeller University, New York, New York, USA.
Departments of Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
Center for Hypothalamic Research and Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
| | - Esra Asilmaz
- Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
Laboratory of Molecular Genetics, The Rockefeller University, New York, New York, USA.
Departments of Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
Center for Hypothalamic Research and Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
| | - Jiang Hu
- Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
Laboratory of Molecular Genetics, The Rockefeller University, New York, New York, USA.
Departments of Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
Center for Hypothalamic Research and Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
| | - John F. Dishinger
- Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
Laboratory of Molecular Genetics, The Rockefeller University, New York, New York, USA.
Departments of Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
Center for Hypothalamic Research and Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
| | - Amarnath J. Kurpad
- Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
Laboratory of Molecular Genetics, The Rockefeller University, New York, New York, USA.
Departments of Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
Center for Hypothalamic Research and Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
| | - Carol F. Elias
- Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
Laboratory of Molecular Genetics, The Rockefeller University, New York, New York, USA.
Departments of Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
Center for Hypothalamic Research and Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
| | - Hui Li
- Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
Laboratory of Molecular Genetics, The Rockefeller University, New York, New York, USA.
Departments of Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
Center for Hypothalamic Research and Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
| | - Joel K. Elmquist
- Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
Laboratory of Molecular Genetics, The Rockefeller University, New York, New York, USA.
Departments of Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
Center for Hypothalamic Research and Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
| | - Robert T. Kennedy
- Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
Laboratory of Molecular Genetics, The Rockefeller University, New York, New York, USA.
Departments of Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
Center for Hypothalamic Research and Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
| | - Rohit N. Kulkarni
- Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
Laboratory of Molecular Genetics, The Rockefeller University, New York, New York, USA.
Departments of Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
Center for Hypothalamic Research and Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
| |
Collapse
|
258
|
Alejandro EU, Johnson JD. Inhibition of Raf-1 alters multiple downstream pathways to induce pancreatic beta-cell apoptosis. J Biol Chem 2007; 283:2407-17. [PMID: 18006502 DOI: 10.1074/jbc.m703612200] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The serine threonine kinase Raf-1 plays a protective role in many cell types, but its function in pancreatic beta-cells has not been elucidated. In the present study, we examined whether primary beta-cells possess Raf-1 and tested the hypothesis that Raf-1 is critical for beta-cell survival. Using reverse transcriptase-PCR, Western blot, and immunofluorescence, we identified Raf-1 in human islets, mouse islets, and in the MIN6 beta-cell line. Blocking Raf-1 activity using a specific Raf-1 inhibitor or dominant-negative Raf-1 mutants led to a time- and dose-dependent increase in cell death, assessed by real-time imaging of propidium iodide incorporation, TUNEL, PCR-enhanced DNA laddering, and Caspase-3 cleavage. Although the rapid increase in apoptotic cell death was associated with decreased Erk phosphorylation, studies with two Mek inhibitors suggested that the classical Erk-dependent pathway could explain only part of the cell death observed after inhibition of Raf-1. An alternative Erk-independent pathway downstream of Raf-1 kinase involving the pro-apoptotic protein Bad has recently been characterized in other tissues. Inhibiting Raf-1 in beta-cells led to a striking loss of Bad phosphorylation at serine 112 and an increase in the protein levels of both Bad and Bax. Together, our data strongly suggest that Raf-1 signaling plays an important role regulating beta-cell survival, via both Erk-dependent and Bad-dependent mechanisms. Conversely, acutely inhibiting phosphatidylinositol 3-kinase Akt had more modest effects on beta-cell death. These studies identify Raf-1 as a critical anti-apoptotic kinase in pancreatic beta-cells and contribute to our understanding of survival signaling in this cell type.
Collapse
Affiliation(s)
- Emilyn U Alejandro
- Laboratory of Molecular Signaling in Diabetes, Diabetes Research Group, Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada
| | | |
Collapse
|
259
|
Liu JL. Does IGF-I stimulate pancreatic islet cell growth? Cell Biochem Biophys 2007; 48:115-25. [PMID: 17709881 DOI: 10.1007/s12013-007-0016-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/1999] [Revised: 11/30/1999] [Accepted: 11/30/1999] [Indexed: 12/22/2022]
Abstract
Both IGF-I and its receptor (IGF-IR) are specifically expressed in various cell types of the endocrine pancreas. IGF-I has long been considered a growth factor for islet cells as it induces DNA synthesis in a glucose-dependent manner, prevents Fas-mediated autoimmune beta-cell destruction and delays onset of diabetes in non-obese diabetic (NOD) mice. Islet-specific IGF-I overexpression promotes islet cell regeneration in diabetic mice. However, in the last few years, results from most gene-targeted mice have challenged this view. For instance, combined inactivation of insulin receptor and IGF-IR or IGF-I and IGF-II genes in early embryos results in no defect on islet cell development; islet beta-cell-specific inactivation of IGF-IR gene causes no change in beta-cell mass; liver- and pancreatic-specific IGF-I gene deficiency (LID and PID mice) suggests that IGF-I exerts an inhibitory effect on islet cell growth albeit indirectly through controlling growth hormone release or expression of Reg family genes. These results need to be evaluated with potential gene redundancy, model limitations, indirect effects and ligand-receptor cross-activations within the insulin/IGF family. Although IGF-I causes islet beta-cell proliferation and neogenesis directly, what occur in normal physiology, pathophysiology or during development of an organism might be different. Locally produced and systemic IGF-I does not seem to play a positive role in islet cell growth. Rather, it is probably a negative regulator through controlling growth hormone and insulin release, hyperglycemia, or Reg gene expression. These results complicate the perspective of an IGF-I therapy for beta-cell loss.
Collapse
Affiliation(s)
- Jun-Li Liu
- Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.
| |
Collapse
|
260
|
Fiaschi-Taesch N, Stewart AF, Garcia-Ocaña A. Improving islet transplantation by gene delivery of hepatocyte growth factor (HGF) and its downstream target, protein kinase B (PKB)/Akt. Cell Biochem Biophys 2007; 48:191-9. [PMID: 17709889 DOI: 10.1007/s12013-007-0024-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/1999] [Revised: 11/30/1999] [Accepted: 11/30/1999] [Indexed: 12/31/2022]
Abstract
Clinical studies have demonstrated that islet transplantation may be a useful procedure to replace beta cell function in patients with Type 1 diabetes. Islet transplantation faces many challenges, including complications associated with the procedure itself, the toxicity of immunosuppression regimens, and to the loss of islet function and insulin-independence with time. Despite the current successes, and residual challenges, these studies have pointed out an enormous scarcity of islet tissue that precludes the use of islet transplantation in a clinical setting on a wider scale. To address this problem, many research groups are trying to identify different islet growth factors and intracellular molecules capable of improving islet graft survival and function, therefore reducing the number of islets needed for successful transplantation. Among these growth factors, hepatocyte growth factor (HGF), a factor known to improve transplantation of a variety of organs/cells, has shown promising results in increasing islet graft survival and reducing the number of islets needed for successful transplantation in four different rodent models of islet transplantation. Protein kinase B (PKB)/Akt, a pro-survival intracellular signaling molecule is known to be activated in the beta cell by several different growth factors, including HGF. PKB/Akt has also shown promising results for improving human islet graft survival and function in a minimal islet mass model of islet transplantation in diabetic SCID mice. Increasing our knowledge on how HGF, PKB/Akt and other emerging molecules work for improving islet transplantation may provide substrate for future therapeutic approaches aimed at increasing the number of patients in which beta cell function can be successfully replaced.
Collapse
|
261
|
Elghazi L, Rachdi L, Weiss AJ, Cras-Méneur C, Bernal-Mizrachi E. Regulation of beta-cell mass and function by the Akt/protein kinase B signalling pathway. Diabetes Obes Metab 2007; 9 Suppl 2:147-57. [PMID: 17919189 DOI: 10.1111/j.1463-1326.2007.00783.x] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The insulin receptor substrate-2/phosphoinositide 3-kinase (PI3K) pathway plays a critical role in the regulation of beta-cell mass and function, demonstrated both in vitro and in vivo. The serine threonine kinase Akt is one of the promising downstream molecules of this pathway that has been identified as a potential target to regulate function and induce proliferation and survival of beta cells. Here we summarize some of the molecular mechanisms, downstream signalling pathways and critical components involved in the regulation of beta-cell mass and function by Akt.
Collapse
Affiliation(s)
- L Elghazi
- Department of Internal Medicine, Division of Endocrinology, Washington University School of Medicine, Metabolism & Lipid Research, St Louis, MO 63110, USA
| | | | | | | | | |
Collapse
|
262
|
Cahuana GM, Tejedo JR, Hmadcha A, Ramírez R, Cuesta AL, Soria B, Martin F, Bedoya FJ. Nitric oxide mediates the survival action of IGF-1 and insulin in pancreatic beta cells. Cell Signal 2007; 20:301-10. [PMID: 18023142 DOI: 10.1016/j.cellsig.2007.10.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2007] [Revised: 09/26/2007] [Accepted: 10/03/2007] [Indexed: 02/08/2023]
Abstract
Generation of low levels of nitric oxide (NO) contributes to beta cell survival in vitro. The purpose of this study was to explore the link between NO and the survival pathway triggered by insulin-like growth factor-1 (IGF-1) and insulin in insulin producing RINm5F cells and in pancreatic islets. Results show that exposure of cells to IGF-1/insulin protects against serum deprivation-induced apoptosis. This action is prevented with inhibitors of NO generation, PI3K and Akt. Moreover, transfection with the negative dominant form of the tyrosine kinase c-Src abrogates the effect of IGF-1 and insulin on DNA fragmentation. An increase in the expression level of NOS3 protein and in the enzyme activity is observed following exposure of serum-deprived RINm5F cells to IGF-1 and insulin. Phosphorylation of IRS-1, IRS-2 and to less extent IRS-3 takes place when serum-deprived RINm5F cells and rat pancreatic islets are exposed to either IGF-1, insulin, or diethylenetriamine nitric oxide adduct (DETA/NO). In human islets, IRS-1 and IRS-2 proteins are present and tyrosine phosphorylated upon exposure to IGF-1, insulin and DETA/NO. Both rat and human pancreatic islets undergo DNA fragmentation when cultured in serum-free medium and IGF-1, insulin and DETA/NO protect efficiently from this damage. We then conclude that generation of NO participates in the activation of survival pathways by IGF-1 and insulin in beta cells.
Collapse
Affiliation(s)
- Gladys M Cahuana
- Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER)-University Pablo de Olavide, Sevilla, Spain
| | | | | | | | | | | | | | | |
Collapse
|
263
|
Fayard E, Gill J, Paolino M, Hynx D, Holländer GA, Hemmings BA. Deletion of PKBalpha/Akt1 affects thymic development. PLoS One 2007; 2:e992. [PMID: 17912369 PMCID: PMC1991598 DOI: 10.1371/journal.pone.0000992] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2007] [Accepted: 09/04/2007] [Indexed: 12/31/2022] Open
Abstract
Background The thymus constitutes the primary lymphoid organ for the majority of T cells. The phosphatidyl-inositol 3 kinase (PI3K) signaling pathway is involved in lymphoid development. Defects in single components of this pathway prevent thymocytes from progressing beyond early T cell developmental stages. Protein kinase B (PKB) is the main effector of the PI3K pathway. Methodology/Principal Findings To determine whether PKB mediates PI3K signaling in the thymus, we characterized PKB knockout thymi. Our results reveal a significant thymic hypocellularity in PKBα−/− neonates and an accumulation of early thymocyte subsets in PKBα−/− adult mice. Using thymic grafting and fetal liver cell transfer experiments, the latter finding was specifically attributed to the lack of PKBα within the lymphoid component of the thymus. Microarray analyses show that the absence of PKBα in early thymocyte subsets modifies the expression of genes known to be involved in pre-TCR signaling, in T cell activation, and in the transduction of interferon-mediated signals. Conclusions/Significance This report highlights the specific requirements of PKBα for thymic development and opens up new prospects as to the mechanism downstream of PKBα in early thymocytes.
Collapse
Affiliation(s)
- Elisabeth Fayard
- Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
| | - Jason Gill
- Pediatric Immunology, Center for Biomedicine, Department of Clinical-Biological Sciences, The University of Basel, The University Children's Hospital, Basel, Switzerland
| | - Magdalena Paolino
- Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
| | - Debby Hynx
- Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
| | - Georg A. Holländer
- Pediatric Immunology, Center for Biomedicine, Department of Clinical-Biological Sciences, The University of Basel, The University Children's Hospital, Basel, Switzerland
| | - Brian A. Hemmings
- Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
- * To whom correspondence should be addressed. E-mail:
| |
Collapse
|
264
|
Ballian N, Hu M, Liu SH, Brunicardi FC. Proliferation, hyperplasia, neogenesis, and neoplasia in the islets of Langerhans. Pancreas 2007; 35:199-206. [PMID: 17895838 DOI: 10.1097/mpa.0b013e318074c6ed] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Pancreatic disease is responsible for significant morbidity and mortality as a result of pancreatic carcinoma and diabetes mellitus. Regulation of endocrine cell mass is thought to have a central role in the pathogenesis of both these diseases. Islet cell proliferation, hypertrophy, neogenesis, and apoptosis are the main determinants of endocrine cell mass in the pancreas, and their understanding has been improved by new clues of their genetic and molecular basis. Beta cells have attracted most research interest because of potential implications in the treatment of diabetes mellitus and hypoglycemic disorders. The processes that operate during pancreatic adaptation to a changing hormonal milieu are important in pancreatic carcinogenesis. There is evidence that somatostatin and its receptors are fundamental regulators of endocrine cell mass and are involved in islet tumorigenesis.
Collapse
Affiliation(s)
- Nikiforos Ballian
- Department of Surgery, The Johns Hopkins Hospital, Baltimore, MD, USA
| | | | | | | |
Collapse
|
265
|
Liadis N, Salmena L, Kwan E, Tajmir P, Schroer SA, Radziszewska A, Li X, Sheu L, Eweida M, Xu S, Gaisano HY, Hakem R, Woo M. Distinct in vivo roles of caspase-8 in beta-cells in physiological and diabetes models. Diabetes 2007; 56:2302-11. [PMID: 17563067 DOI: 10.2337/db06-1771] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Inadequate pancreatic beta-cell mass resulting from excessive beta-cell apoptosis is a key defect in type 1 and type 2 diabetes. Caspases are the major molecules involved in apoptosis; however, in vivo roles of specific caspases in diabetes are unclear. The purpose of this study is to examine the role of Caspase (Casp)8 in beta-cells in vivo. Using the Cre-loxP system, mice lacking Casp8 in beta-cells (RIPcre(+)Casp8(fl/fl) mice) were generated to address the role of Casp8 in beta-cells in physiological and diabetes models. We show that islets isolated from RIPcre(+)Casp8(fl/fl) mice were protected from Fas ligand (FasL)-and ceramide-induced cell death. Furthermore, RIPcre(+)Casp8(fl/fl) mice were protected from in vivo models of type 1 and type 2 diabetes. In addition to being the central mediator of apoptosis in diabetes models, we show that Casp8 is critical for maintenance of beta-cell mass under physiological conditions. With aging, RIPcre(+)Casp8(fl/fl) mice gradually develop hyperglycemia and a concomitant decline in beta-cell mass. Their islets display decreased expression of molecules involved in insulin/IGF-I signaling and show decreased pancreatic duodenal homeobox-1 and cAMP response element binding protein expression. At the level of individual islets, we observed increased insulin secretory capacity associated with increased expression of exocytotic proteins. Our results show distinct context-specific roles of Casp8 in physiological and disease states; Casp8 is essential for beta-cell apoptosis in type 1 and type 2 diabetes models and in regulating beta-cell mass and insulin secretion under physiological conditions.
Collapse
Affiliation(s)
- Nicole Liadis
- Department of Medical Biophysics, Ontario Cancer Institute, and the University of Toronto, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
266
|
Calderari S, Gangnerau MN, Thibault M, Meile MJ, Kassis N, Alvarez C, Portha B, Serradas P. Defective IGF2 and IGF1R protein production in embryonic pancreas precedes beta cell mass anomaly in the Goto-Kakizaki rat model of type 2 diabetes. Diabetologia 2007; 50:1463-71. [PMID: 17476475 DOI: 10.1007/s00125-007-0676-2] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2006] [Accepted: 02/04/2007] [Indexed: 12/31/2022]
Abstract
AIMS/HYPOTHESIS The Goto-Kakizaki (GK) rat is a spontaneous model of type 2 diabetes. Defective beta cell mass detectable in late fetal age precedes the onset of hyperglycaemia. Our hypothesis was that an embryonic IGF production deficiency might be involved in beta cell mass anomaly in the diabetic GK rat. To test this, we evaluated during pancreatic organogenesis: (1) the beta cell development in GK rats on embryonic day (E) 13.5 and E18.5; (2) IGF2 and IGF1 receptor (IGF1R) pancreatic protein production on E13.5 and E18.5; (3) the in vitro development of GK pancreatic rudiment on E13.5; and (4) the in vitro effect of IGF2 addition on beta cell mass. MATERIALS AND METHODS Beta cell quantitative analyses were determined by immunohistochemistry and morphometry. IGF2 and IGF1R pancreatic protein production was evaluated using western blot analyses. Dorsal pancreatic rudiments were dissected on E13.5, separated from surrounding mesenchyme and cultured for 7 days without or with recombinant IGF2. RESULTS While beta cell mass was already decreased on E18.5, the differentiation of the first beta cells was in fact normal in E13.5 GK pancreas. Moreover, defective IGF2 and IGF1R protein production was detected in GK pancreatic rudiment as early as E13.5. The isolated GK pancreatic rudiment as maintained in vitro mimics the GK beta cell deficiency observed in vivo. This last approach enabled us to show that GK beta cells were fully responsive to IGF2 as far as their net growth is concerned. CONCLUSIONS/INTERPRETATION In diabetic GK rat, defective IGF2 and IGF1R protein production in embryonic pancreas precedes beta cell mass anomaly. IGF2 supplementation expands the pool of beta cells.
Collapse
Affiliation(s)
- S Calderari
- Laboratory of Physiopathology of Nutrition, UMR CNRS 7059, University of Paris 7, 2 place Jussieu, 75251, Paris Cedex 05, France.
| | | | | | | | | | | | | | | |
Collapse
|
267
|
Feanny MA, Fagan SP, Ballian N, Liu SH, Li Z, Wang X, Fisher W, Brunicardi FC, Belaguli NS. PDX-1 expression is associated with islet proliferation in vitro and in vivo. J Surg Res 2007; 144:8-16. [PMID: 17583748 DOI: 10.1016/j.jss.2007.04.018] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2006] [Revised: 03/21/2007] [Accepted: 04/08/2007] [Indexed: 12/31/2022]
Abstract
BACKGROUND Transcription factor pancreatic duodenal homeobox-1 (PDX-1) is critical for beta-cell differentiation and insulin gene expression. In this study, we investigated the role of PDX-1 in ductal-to-islet cell transdifferentiation, islet cell apoptosis, and proliferation in addition to other regulators associated with these processes in two developing beta-cell models. MATERIALS AND METHODS CAPAN-1 cells were cultured with the GLP-1 analogue Exendin-4 (Ex-4) to induce transdifferentiation to an insulin-producing phenotype. Expression patterns of PDX-1, somatostatin receptors (SSTR) 1, 2, and 5, p27, and p38 were analyzed. To model pancreatic regeneration in vivo, subtotal pancreatectomies were performed in rats and remnant pancreata were compared to sham laparotomy controls to determine islet size, morphology, apoptosis, and PDX-1 expression. RESULTS In Ex-4-treated cells, PDX-1 expression increased 67% above basal levels within 24 h and was followed by a 10-fold decline in expression by the end of the study. Expression of cell-cycle inhibitor p27 was down-regulated by 81% at 24 h, while levels of the pro-apoptotic modulator p38 significantly increased 4-fold. When compared to controls, SSTR1 expression declined, while SSTR2 and SSTR5 expression were significantly up-regulated in treated cells. Immunofluorescence of pancreatic remnants following subtotal pancreatectomy revealed increased PDX-1 staining at 24 h followed by a significant decline at 72 h post-pancreatectomy. CONCLUSION GLP-1 analogue Ex-4 resulted in up-regulation of PDX-1 in CAPAN-1 cells and PDX-1 was up-regulated in proliferating islets following subtotal pancreatectomy in rats. The increase was seen in the first 24 h. These findings suggest a possible relationship between PDX-1 and the state of islet proliferation, islet-to-ductal transdifferentiation, apoptosis, and the expression of SSTRs.
Collapse
Affiliation(s)
- Mark A Feanny
- The Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
268
|
Okada T, Liew CW, Hu J, Hinault C, Michael MD, Kr̈tzfeldt J, Yin C, Holzenberger M, Stoffel M, Kulkarni RN. Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. Proc Natl Acad Sci U S A 2007; 104:8977-82. [PMID: 17416680 PMCID: PMC1885613 DOI: 10.1073/pnas.0608703104] [Citation(s) in RCA: 222] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2006] [Indexed: 12/31/2022] Open
Abstract
Insulin and insulin-like growth factor 1 (IGF1) are ubiquitous growth factors that regulate proliferation in most mammalian tissues including pancreatic islets. To explore the specificity of insulin receptors in compensatory beta-cell growth, we examined two models of insulin resistance. In the first model, we used liver-specific insulin receptor knockout (LIRKO) mice, which exhibit hyperinsulinemia without developing diabetes due to a compensatory increase in beta-cell mass. LIRKO mice, also lacking functional insulin receptors in beta-cells (beta IRKO/LIRKO), exhibited severe glucose intolerance but failed to develop compensatory islet hyperplasia, together leading to early death. In the second model, we examined the relative significance of insulin versus IGF1 receptors in islet growth by feeding high-fat diets to beta IRKO and beta-cell-specific IGF1 receptor knockout (beta IGFRKO) mice. Although both groups on the high-fat diet developed insulin resistance, beta IRKO, but not beta IGFRKO, mice exhibited poor islet growth consistent with insulin-stimulated phosphorylation, nuclear exclusion of FoxO1, and reduced expression of Pdx-1. Together these data provide direct genetic evidence that insulin/FoxO1/Pdx-1 signaling is one pathway that is crucial for islet compensatory growth response to insulin resistance.
Collapse
Affiliation(s)
- Terumasa Okada
- *Research Division, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02215
| | - Chong Wee Liew
- *Research Division, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02215
| | - Jiang Hu
- *Research Division, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02215
| | - Charlotte Hinault
- *Research Division, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02215
| | - M. Dodson Michael
- *Research Division, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02215
| | - Jan Kr̈tzfeldt
- Laboratory of Metabolic Diseases, Rockefeller University, New York, NY 10021; and
| | - Catherine Yin
- *Research Division, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02215
| | | | - Markus Stoffel
- Laboratory of Metabolic Diseases, Rockefeller University, New York, NY 10021; and
| | - Rohit N. Kulkarni
- *Research Division, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02215
| |
Collapse
|
269
|
Mullany LK, Nelsen CJ, Hanse EA, Goggin MM, Anttila CK, Peterson M, Bitterman PB, Raghavan A, Crary GS, Albrecht JH. Akt-mediated liver growth promotes induction of cyclin E through a novel translational mechanism and a p21-mediated cell cycle arrest. J Biol Chem 2007; 282:21244-52. [PMID: 17517888 DOI: 10.1074/jbc.m702110200] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The control of hepatocyte growth is relevant to the processes of liver regeneration, development, metabolic homeostasis, and cancer. A key component of growth control is the protein kinase Akt, which acts downstream of mitogens and nutrients to affect protein translation and cell cycle progression. In this study, we found that transient transfection of activated Akt triggered a 3-4-fold increase in liver size within days but only minimal hepatocyte proliferation. Akt-induced liver growth was associated with marked up-regulation of cyclin E but not cyclin D1. Analysis of liver polyribosomes demonstrated that the post-transcriptional induction of cyclin E was associated with increased translational efficiency of this mRNA, suggesting that cell growth promotes expression of this protein through a translational mechanism that is distinct from the cyclin D-E2F pathway. Treatment of Akt-transfected mice with rapamycin only partially inhibited liver growth and did not prevent the induction of cyclin E protein, indicating that target of rapamycin activity is not necessary for this response. In the enlarged livers, cyclin E-Cdk2 complexes were present in high abundance but were inactive due to increased binding of p21 to these complexes. Akt transfection of p21(-/-) mice promoted liver growth, activation of Cdk2, and enhanced hepatocyte proliferation. In conclusion, growth promotes cyclin E expression through a novel translational mechanism in the liver, suggesting a new link between cell growth and the cell cycle machinery. Furthermore, p21 suppresses proliferation in the overgrown livers and may play a role in preventing cell cycle progression in response to organ size homeostatic mechanisms.
Collapse
Affiliation(s)
- Lisa K Mullany
- Division of Gastroenterology, Hennepin County Medical Center, Minneapolis, Minnesota 55415, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
270
|
Terauchi Y, Takamoto I, Kubota N, Matsui J, Suzuki R, Komeda K, Hara A, Toyoda Y, Miwa I, Aizawa S, Tsutsumi S, Tsubamoto Y, Hashimoto S, Eto K, Nakamura A, Noda M, Tobe K, Aburatani H, Nagai R, Kadowaki T. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 2007; 117:246-57. [PMID: 17200721 PMCID: PMC1716196 DOI: 10.1172/jci17645] [Citation(s) in RCA: 263] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2002] [Accepted: 11/07/2006] [Indexed: 12/31/2022] Open
Abstract
Glucokinase (Gck) functions as a glucose sensor for insulin secretion, and in mice fed standard chow, haploinsufficiency of beta cell-specific Gck (Gck(+/-)) causes impaired insulin secretion to glucose, although the animals have a normal beta cell mass. When fed a high-fat (HF) diet, wild-type mice showed marked beta cell hyperplasia, whereas Gck(+/-) mice demonstrated decreased beta cell replication and insufficient beta cell hyperplasia despite showing a similar degree of insulin resistance. DNA chip analysis revealed decreased insulin receptor substrate 2 (Irs2) expression in HF diet-fed Gck(+/-) mouse islets compared with wild-type islets. Western blot analyses confirmed upregulated Irs2 expression in the islets of HF diet-fed wild-type mice compared with those fed standard chow and reduced expression in HF diet-fed Gck(+/-) mice compared with those of HF diet-fed wild-type mice. HF diet-fed Irs2(+/-) mice failed to show a sufficient increase in beta cell mass, and overexpression of Irs2 in beta cells of HF diet-fed Gck(+/-) mice partially prevented diabetes by increasing beta cell mass. These results suggest that Gck and Irs2 are critical requirements for beta cell hyperplasia to occur in response to HF diet-induced insulin resistance.
Collapse
Affiliation(s)
- Yasuo Terauchi
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Iseki Takamoto
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Naoto Kubota
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Junji Matsui
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Ryo Suzuki
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Kajuro Komeda
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Akemi Hara
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Yukiyasu Toyoda
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Ichitomo Miwa
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Shinichi Aizawa
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Shuichi Tsutsumi
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Yoshiharu Tsubamoto
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Shinji Hashimoto
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Kazuhiro Eto
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Akinobu Nakamura
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Mitsuhiko Noda
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Kazuyuki Tobe
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Hiroyuki Aburatani
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Ryozo Nagai
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Takashi Kadowaki
- Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Saitama, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Division of Applied Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Division of Laboratory Animal Science, Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Laboratory for Vertebrate Body Plan, Center for Developmental Biology, Institute of Physical and Chemical Research (RIKEN), Kobe, Japan.
Genome Science Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| |
Collapse
|
271
|
Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007; 113:546-93. [PMID: 17306374 PMCID: PMC1934514 DOI: 10.1016/j.pharmthera.2006.11.007] [Citation(s) in RCA: 482] [Impact Index Per Article: 28.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2006] [Accepted: 11/27/2006] [Indexed: 12/13/2022]
Abstract
Glucagon-like peptide 1 (GLP-1) is a hormone that is encoded in the proglucagon gene. It is mainly produced in enteroendocrine L cells of the gut and is secreted into the blood stream when food containing fat, protein hydrolysate, and/or glucose enters the duodenum. Its particular effects on insulin and glucagon secretion have generated a flurry of research activity over the past 20 years culminating in a naturally occurring GLP-1 receptor (GLP-1R) agonist, exendin 4 (Ex-4), now being used to treat type 2 diabetes mellitus (T2DM). GLP-1 engages a specific guanine nucleotide-binding protein (G-protein) coupled receptor (GPCR) that is present in tissues other than the pancreas (brain, kidney, lung, heart, and major blood vessels). The most widely studied cell activated by GLP-1 is the insulin-secreting beta cell where its defining action is augmentation of glucose-induced insulin secretion. Upon GLP-1R activation, adenylyl cyclase (AC) is activated and cAMP is generated, leading, in turn, to cAMP-dependent activation of second messenger pathways, such as the protein kinase A (PKA) and Epac pathways. As well as short-term effects of enhancing glucose-induced insulin secretion, continuous GLP-1R activation also increases insulin synthesis, beta cell proliferation, and neogenesis. Although these latter effects cannot be currently monitored in humans, there are substantial improvements in glucose tolerance and increases in both first phase and plateau phase insulin secretory responses in T2DM patients treated with Ex-4. This review will focus on the effects resulting from GLP-1R activation in the pancreas.
Collapse
Affiliation(s)
- Máire E Doyle
- Department of Pathology, Immunology & Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | | |
Collapse
|
272
|
Metz TO, Jacobs JM, Gritsenko MA, Fontès G, Qian WJ, Camp DG, Poitout V, Smith RD. Characterization of the human pancreatic islet proteome by two-dimensional LC/MS/MS. J Proteome Res 2007; 5:3345-54. [PMID: 17137336 PMCID: PMC2975945 DOI: 10.1021/pr060322n] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The pancreatic beta-cell plays a central role in the maintenance of glucose homeostasis and in the pathogenesis of both type 1 and type 2 diabetes mellitus. Elucidation of the insulin secretory defects observed in diabetes first requires a better understanding of the complex mechanisms regulating insulin secretion, which are only partly understood. While there have been reports detailing proteomic analyses of islet cell lines or isolated rodent islets, the information gained is not always applicable to humans. Therefore, definition of the human islet proteome could contribute to a better understanding of islet biology and lead to more effective treatment strategies. We have applied a two-dimensional LC-MS/MS-based analysis to the characterization of the human islet proteome, resulting in the confident identification of 29,021 different tryptic peptides covering 3365 proteins (> or =2 unique peptide identifications per protein). As expected, the three major islet hormones (insulin, glucagon, and somatostatin) were detected, as well as various beta-cell enriched secretory products, ion channels, and transcription factors. In addition, significant proteome coverage of metabolic enzymes and cellular pathways was observed, including the integrin signaling cascade and the MAP kinase, NF-kappa beta, and JAK/STAT pathways. The resulting peptide reference library provides a resource for future higher throughput and quantitative studies of islet biology.
Collapse
Affiliation(s)
- Thomas O. Metz
- Biological Science Division and Environmental Molecular Sciences Laboratory Pacific Northwest National Laboratory Richland, Washington, USA
| | - Jon M. Jacobs
- Biological Science Division and Environmental Molecular Sciences Laboratory Pacific Northwest National Laboratory Richland, Washington, USA
| | - Marina A. Gritsenko
- Biological Science Division and Environmental Molecular Sciences Laboratory Pacific Northwest National Laboratory Richland, Washington, USA
| | | | - Wei-Jun Qian
- Biological Science Division and Environmental Molecular Sciences Laboratory Pacific Northwest National Laboratory Richland, Washington, USA
| | - David G. Camp
- Biological Science Division and Environmental Molecular Sciences Laboratory Pacific Northwest National Laboratory Richland, Washington, USA
| | - Vincent Poitout
- Pacific Northwest Research Institute, Seattle, Washington, USA
| | - Richard D. Smith
- Biological Science Division and Environmental Molecular Sciences Laboratory Pacific Northwest National Laboratory Richland, Washington, USA
- Corresponding author: P.O. Box 999 Richland, WA 99352 Phone: (509) 376-0723 Fax: (509) 376-2303
| |
Collapse
|
273
|
Shiojima I, Walsh K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev 2007; 20:3347-65. [PMID: 17182864 DOI: 10.1101/gad.1492806] [Citation(s) in RCA: 285] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Postnatal growth of the heart is primarily achieved through hypertrophy of individual myocytes. Cardiac growth observed in athletes represents adaptive or physiological hypertrophy, whereas cardiac growth observed in patients with hypertension or valvular heart diseases is called maladaptive or pathological hypertrophy. These two types of hypertrophy are morphologically, functionally, and molecularly distinct from each other. The serine/threonine protein kinase Akt is activated by various extracellular stimuli in a phosphatidylinositol-3 kinase-dependent manner and regulates multiple aspects of cellular functions including survival, growth and metabolism. In this review we will discuss the role of the Akt signaling pathway in the heart, focusing on the regulation of cardiac growth, contractile function, and coronary angiogenesis. How this signaling pathway contributes to the development of physiological/pathological hypertrophy and heart failure will also be discussed.
Collapse
Affiliation(s)
- Ichiro Shiojima
- Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
| | | |
Collapse
|
274
|
Mussmann R, Geese M, Harder F, Kegel S, Andag U, Lomow A, Burk U, Onichtchouk D, Dohrmann C, Austen M. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J Biol Chem 2007; 282:12030-7. [PMID: 17242403 DOI: 10.1074/jbc.m609637200] [Citation(s) in RCA: 116] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Recent developments indicate that the regeneration of beta cell function and mass in patients with diabetes is possible. A regenerative approach may represent an alternative treatment option relative to current diabetes therapies that fail to provide optimal glycemic control. Here we report that the inactivation of GSK3 by small molecule inhibitors or RNA interference stimulates replication of INS-1E rat insulinoma cells. Specific and potent GSK3 inhibitors also alleviate the toxic effects of high concentrations of glucose and the saturated fatty acid palmitate on INS-1E cells. Furthermore, treatment of isolated rat islets with structurally diverse small molecule GSK3 inhibitors increases the rate beta cell replication by 2-3-fold relative to controls. We propose that GSK3 is a regulator of beta cell replication and survival. Moreover, our results suggest that specific inhibitors of GSK3 may have practical applications in beta cell regenerative therapies.
Collapse
Affiliation(s)
- Rainer Mussmann
- DeveloGen AG, Marie-Curie-Strasse 7, Göttingen 37079, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
275
|
Hettiarachchi KD, Zimmet PZ, Myers MA. The plecomacrolide vacuolar-ATPase inhibitor bafilomycin, alters insulin signaling in MIN6 beta-cells. Cell Biol Toxicol 2007; 22:169-81. [PMID: 16555000 DOI: 10.1007/s10565-006-0054-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2005] [Accepted: 01/05/2006] [Indexed: 12/31/2022]
Abstract
Inhibition of endosomal acidification disturbs insulin signaling in both liver and adipose cells. In this study we used MIN6 beta cells to determine whether bafilomycin, a potent inhibitor of the proton-translocating vacuolar ATPase, disrupts insulin signaling in islet beta cells. Pretreatment of MIN6 cells with varying concentrations of bafilomycin according to a time course revealed concentration and time-dependent changes in phosphorylation of insulin receptor signaling components. Increased phosphorylation of insulin receptor (IR), IRS2 and Akt was prolonged at low bafilomycin concentrations (10 and 50 nmol/L), whereas at high concentrations (100 and 200 nmol/L) phosphorylation rapidly returned to basal levels or below. Akt activation was demonstrated by transient increases in phosphorylation of BAD, cytoplasmic retention of FoxO1 and increased preproinsulin mRNA. Bcl2 expression was also transiently increased but reduced after 30 min exposure to bafilomycin, and this coincided with reduced cell viability. Thus, in beta cells inhibition of endosomal acidification by low concentrations of bafilomycin transiently increases insulin signaling, whereas high concentrations promote cell death. Bafilomycin and other agents that interfere with insulin signaling may contribute to diabetes development through disturbing homeostatic control of beta cell growth.
Collapse
Affiliation(s)
- K D Hettiarachchi
- Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia
| | | | | |
Collapse
|
276
|
Jiang H, Zhu H, Chen X, Peng Y, Wang J, Liu F, Shi S, Fu B, Lu Y, Hong Q, Feng Z, Hou K, Sun X, Cai G, Zhang X, Xie Y. TIMP-1 transgenic mice recover from diabetes induced by multiple low-dose streptozotocin. Diabetes 2007; 56:49-56. [PMID: 17192464 DOI: 10.2337/db06-0710] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Type 1 diabetes results from autoimmune destruction of the insulin-producing beta-cells of pancreatic islets, of which the capacity for self-replication in the adult is too limited to restore following extensive tissue injury. Tissue inhibitor of metalloproteinase (TIMP)-1 inhibits matrix metalloproteinase activity and regulates proliferation and apoptosis of a variety of cells types, depending on the context. Here, we show that overexpression of human TIMP-1 in pancreatic beta-cells of transgenic mice counteracts the cytotoxicity and insulitis induced by multiple low-dose streptozotocin (MLDS). Nontransgenic mice developed severe hyperglycemia, hypoinsulinemia, and insulitis 2 weeks after streptozotocin administration and died within 17 weeks. However, MLDS-treated transgenic mice gradually normalized the metabolic parameters and survived. beta-Cell mass increased in parallel as a result of enhancement of beta-cell replication. Thus, our results have demonstrated for the first time that overexpression of TIMP-1 in beta-cells enhances the replication of pancreatic islets beta-cells and counteracts type 1 diabetes, indicating that the TIMP-1 gene may be a potential target to prevent, or even reverse, type 1 diabetes.
Collapse
Affiliation(s)
- Hongwei Jiang
- Department of Nephrology, Kidney Center and Key Lab of People's Liberation Army, General Hospital of PLA, Fuxing Road 28, Beijing 100853, PR China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
277
|
Fernández E, Martín MA, Fajardo S, Escrivá F, Alvarez C. Increased IRS-2 content and activation of IGF-I pathway contribute to enhance beta-cell mass in fetuses from undernourished pregnant rats. Am J Physiol Endocrinol Metab 2007; 292:E187-95. [PMID: 16912057 DOI: 10.1152/ajpendo.00283.2006] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
We have previously shown that fetuses from undernourished (U) pregnant rats exhibited an increased beta-cell mass probably related to an enhanced IGF-I replicative response. Because IGF-I signaling pathways have been implicated in regulating beta-cell growth, we investigated in this study the IGF-I transduction system in U fetuses. To this end, an in vitro model of primary fetal islets was developed to characterize glucose/IGF-I-mediated signaling that specially influences beta-cell proliferation. We found that U fetal islets showed a greater replicative response to glucose and IGF-I than controls. Furthermore, insulin receptor substrate (IRS)-2 protein and its association with p85 were also increased. In the complete absence of IGF-I or stimulatory glucose, U islets presented an increased basal phosphorylation of downstream signals of the phosphatidylinositol 3-kinase (PI3K) pathway such as PKB, glycogen synthase kinase (GSK)3alpha/beta, PKCzeta, and mammalian target of rapamycin (mTOR). Similarly, phosphorylation of these proteins (except GSK3alpha/beta) by glucose and IGF-I was augmented even though total protein content remained unchanged. Downstream of PKB, direct glucose activation of mTOR was increased as well. In contrast, ERK1/2 phosphorylation was unaffected by undernutrition, but ERK activation seemed to be required to induce a higher proliferative response in U islets. In conclusion, we have demonstrated that fetal U islets show increased IRS-2 content and an enhancement in both basal and glucose/IGF-I activations of the IRS-2/PI3K/PKB pathway. These molecular changes may be responsible for the greater glucose/IGF-I islet replication and contribute to the increased beta-cell mass found in these fetuses.
Collapse
Affiliation(s)
- Elisa Fernández
- Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad Complutense, Ciudad Universitaria, 28040 Madrid, Spain
| | | | | | | | | |
Collapse
|
278
|
Peshavaria M, Larmie BL, Lausier J, Satish B, Habibovic A, Roskens V, Larock K, Everill B, Leahy JL, Jetton TL. Regulation of pancreatic beta-cell regeneration in the normoglycemic 60% partial-pancreatectomy mouse. Diabetes 2006; 55:3289-98. [PMID: 17130472 DOI: 10.2337/db06-0017] [Citation(s) in RCA: 99] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
beta-Cell mass is determined by a dynamic balance of proliferation, neogenesis, and apoptosis. The precise mechanisms underlying compensatory beta-cell mass (BCM) homeostasis are not fully understood. To evaluate the processes that maintain normoglycemia and regulate BCM during pancreatic regeneration, C57BL/6 mice were analyzed for 15 days following 60% partial pancreatectomy (Px). BCM increased in Px mice from 2 days onwards and was approximately 68% of the shams by 15 days, partly due to enhanced beta-cell proliferation. A transient approximately 2.8-fold increase in the prevalence of beta-cell clusters/small islets at 2 days post-Px contributed substantially to BCM augmentation, followed by an increase in the number of larger islets at 15 days. To evaluate the signaling mechanisms that may regulate this compensatory growth, we examined key intermediates of the insulin signaling pathway. We found insulin receptor substrate (IRS)2 and enhanced-activated Akt immunoreactivity in islets and ducts that correlated with increased pancreatic duodenal homeobox (PDX)1 expression. In contrast, forkhead box O1 expression was decreased in islets but increased in ducts, suggesting distinct PDX1 regulatory mechanisms in these tissues. Px animals acutely administered insulin exhibited further enhancement in insulin signaling activity. These data suggest that the IRS2-Akt pathway mediates compensatory beta-cell growth by activating beta-cell proliferation with an increase in the number of beta-cell clusters/small islets.
Collapse
Affiliation(s)
- Mina Peshavaria
- University of Vermont College of Medicine, Department of Medicine, Given C331, Burlington, VT 05405, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
279
|
Aikin R, Hanley S, Maysinger D, Lipsett M, Castellarin M, Paraskevas S, Rosenberg L. Autocrine insulin action activates Akt and increases survival of isolated human islets. Diabetologia 2006; 49:2900-9. [PMID: 17053882 DOI: 10.1007/s00125-006-0476-0] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2006] [Accepted: 09/08/2006] [Indexed: 12/31/2022]
Abstract
AIMS/HYPOTHESIS The phosphatidylinositol 3-kinase (PI3K)/Akt pathway plays a critical role in promoting the survival of pancreatic beta cells. Akt becomes activated in isolated human islets following overnight culture despite significant levels of cell death. The aim of the current study was to identify the cause of the observed increase in Akt phosphorylation in isolated islets. We hypothesised that a factor secreted by the islets in culture was acting in an autocrine manner to activate Akt. METHODS In order to identify the stimulus of the PI3K/Akt pathway in culture, we examined the effects of different culture conditions on Akt phosphorylation and islet survival during the immediate post-isolation period. RESULTS We demonstrated that islet-conditioned medium induced Akt phosphorylation in freshly isolated human islets, whereas frequent medium replacement decreased Akt phosphorylation. Following overnight culture, islet-conditioned medium contained significantly elevated levels of insulin, indicating that insulin may be responsible for the observed increase in Akt phosphorylation. Indeed, treatment with an anti-insulin antibody or with inhibitors of insulin receptor/IGF receptor 1 kinase activity suppressed Akt phosphorylation, leading to decreased islet survival. In addition, dispersion of islets into single cells also suppressed Akt phosphorylation and induced islet cell death, indicating that islet integrity is also required for maximal Akt phosphorylation. CONCLUSIONS/INTERPRETATION Our findings demonstrate that insulin acts in an autocrine manner to activate Akt and mediate the survival of isolated human islets. These findings provide new information on how culturing islets prior to transplantation may be beneficial to their survival by allowing for autocrine activation of the pro-survival Akt pathway.
Collapse
Affiliation(s)
- R Aikin
- Department of Surgery, McGill University, Montreal, QC, Canada
| | | | | | | | | | | | | |
Collapse
|
280
|
Simeone DM, Zhang L, Treutelaar MK, Zhang L, Graziano K, Logsdon CD, Burant CF. Islet hypertrophy following pancreatic disruption of Smad4 signaling. Am J Physiol Endocrinol Metab 2006; 291:E1305-16. [PMID: 16735447 DOI: 10.1152/ajpendo.00561.2005] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
To investigate the role of transforming growth factor (TGF)-beta family signaling in the adult pancreas, a transgenic mouse (E-dnSmad4) was created that expresses a dominant-negative Smad4 protein driven by a fragment of the elastase promoter. Although E-dnSmad4 mice have normal growth, pancreas weight, and pancreatic exocrine and ductal histology, beginning at 4-6 wk of age, E-dnSmad4 mice show an age-dependent increase in the size of islets. In parallel, an expanded population of replicating cells expressing the E-dnSmad4 transgene is found in the stroma between the enlarged islets and pancreatic ducts. Despite the marked enlargement, E-dnSmad4 islets contain normal ratios and spatial organization of endocrine cell subtypes and have normal glucose homeostasis. Replication of cells derived from primary duct cultures of wild-type mice, but not E-dnSmad4 mice, was inhibited by the addition of TGF-beta family proteins, demonstrating a cell-autonomous effect of the transgene. These data show that, in the adult pancreas, TGF-beta family signaling plays a role in islet size by regulating the growth of a pluripotent progenitor cell residing in the periductal stroma of the pancreas.
Collapse
Affiliation(s)
- Diane M Simeone
- Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA
| | | | | | | | | | | | | |
Collapse
|
281
|
Ries V, Henchcliffe C, Kareva T, Rzhetskaya M, Bland R, During MJ, Kholodilov N, Burke RE. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc Natl Acad Sci U S A 2006; 103:18757-62. [PMID: 17116866 PMCID: PMC1654135 DOI: 10.1073/pnas.0606401103] [Citation(s) in RCA: 138] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Despite promising preclinical studies, neurotrophic factors have not yet achieved an established role in the treatment of human neurodegenerative diseases. One impediment has been the difficulty in providing these macromolecules in sufficient quantity and duration at affected sites. An alternative approach is to directly activate, by viral vector transduction, intracellular signaling pathways that mediate neurotrophic effects. We have evaluated this approach in dopamine neurons of the substantia nigra, neurons affected in Parkinson's disease, by adeno-associated virus 1 transduction with a gene encoding a myristoylated, constitutively active form of the oncoprotein Akt/PKB. Adeno-associated virus Myr-Akt has pronounced trophic effects on dopamine neurons of adult and aged mice, including increases in neuron size, phenotypic markers, and sprouting. Transduction confers almost complete protection against apoptotic cell death in a highly destructive neurotoxin model. Activation of intracellular neurotrophic signaling pathways by vector transfer is a feasible approach to neuroprotection and restorative treatment of neurodegenerative disease.
Collapse
Affiliation(s)
| | | | | | | | | | - Matthew J. During
- Human Cancer Genetics Program, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210
| | | | - Robert E. Burke
- Departments of *Neurology and
- Pathology, Columbia University College of Physicians and Surgeons, New York, NY 10032; and
- To whom correspondence should be addressed at:
Department of Neurology, Room 306, Black Building, Columbia University Medical Center, 650 West 168th Street, New York, NY 10032. E-mail:
| |
Collapse
|
282
|
Huypens PR. Leptin and adiponectin regulate compensatory beta cell growth in accordance to overweight. Med Hypotheses 2006; 68:1134-7. [PMID: 17098372 DOI: 10.1016/j.mehy.2006.09.046] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2006] [Accepted: 09/12/2006] [Indexed: 12/31/2022]
Abstract
Compensatory beta cell growth occurs in accordance to overweight and increasing insulin demands. The proliferative actions of insulin and insulin-like growth factors are mediated via the IRS-2-PI(3)K-Akt pathway of pleiotropic insulin signaling. However, sustained activation leads to negative feedback via the mTOR-induced proteasomal degradation of IRS-2. The proliferative actions of incretins and adipokines are mediated via other pathways that ultimately converge with the IRS-2-PI(3)K-Akt axis. The incretins GIP and GLP-1 increase IRS-2 levels in beta cells by acting via the cAMP-PKA pathway, whereas leptin inhibits PTEN activity via CK2-dependent pathways. By increasing PIP(3) availability the adipokine amplifies the magnitude as well as duration of factors acting via the IRS-2-PI(3)K-Akt pathway. Considering that AMPK prevents mTOR-induced degradation of IRS-2, we propose that adiponectin and leptin cooperatively achieve compensatory beta cell growth in accordance to adiposity. In conditions of overt obesity, when adiponectin levels are too low to provide sufficient IRS-2 levels, loss of compensatory beta cell growth may occur.
Collapse
|
283
|
Pankow S, Bamberger C, Klippel A, Werner S. Regulation of epidermal homeostasis and repair by phosphoinositide 3-kinase. J Cell Sci 2006; 119:4033-46. [PMID: 16968743 DOI: 10.1242/jcs.03175] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The epidermis undergoes continuous self-renewal to maintain its protective function. Whereas growth factors are known to modulate overall skin homeostasis, the intracellular signaling pathways, which control the delicate balance between proliferation and differentiation in keratinocytes, are largely unknown. Here we show transient upregulation of the phosphoinositide 3-kinase (PI3K) catalytic subunits p110α and p110β in differentiating keratinocytes in vitro, expression of these subunits in the epidermis of normal and wounded skin, and enhanced Akt phosphorylation in the hyperproliferative wound epidermis. Stimulation of PI3K activity in cultured keratinocytes by stable expression of an inducible, constitutively active PI3K mutant promoted cell proliferation and inhibited terminal differentiation in keratinocyte monocultures and induced the formation of a hyperplastic, disorganized and poorly differentiated epithelium in organotypic skin cultures. Activation of PI3K signaling also caused reorganization of the actin cytoskeleton and induced keratinocyte migration in vitro and in skin organ cultures. The identification of 122 genes, which are differentially expressed after induction of PI3K signaling provides insight into the molecular mechanisms underlying the observed effects of active PI3K on keratinocytes and indicates that hyperproliferation may be achieved at the expense of genome integrity. These results identify PI3K as an important intracellular regulator of epidermal homeostasis and repair.
Collapse
Affiliation(s)
- Sandra Pankow
- Institute of Cell Biology, Department of Biology, ETH Zurich, CH-8093 Zurich, Switzerland
| | | | | | | |
Collapse
|
284
|
Limesand KH, Schwertfeger KL, Anderson SM. MDM2 is required for suppression of apoptosis by activated Akt1 in salivary acinar cells. Mol Cell Biol 2006; 26:8840-56. [PMID: 16982679 PMCID: PMC1636839 DOI: 10.1128/mcb.01846-05] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Chronic damage to the salivary glands is a common side effect following head and neck irradiation. It is hypothesized that irreversible damage to the salivary glands occurs immediately after radiation; however, previous studies with rat models have not shown a causal role for apoptosis in radiation-induced injury. We report that etoposide and gamma irradiation induce apoptosis of salivary acinar cells from FVB control mice in vitro and in vivo; however, apoptosis is reduced in transgenic mice expressing a constitutively activated mutant of Akt1 (myr-Akt1). Expression of myr-Akt1 in the salivary glands results in a significant reduction in phosphorylation of p53 at serine(18), total p53 protein accumulation, and p21(WAF1) or Bax mRNA following etoposide or gamma irradiation of primary salivary acinar cells. The reduced level of p53 protein in myr-Akt1 salivary glands corresponds with an increase in MDM2 phosphorylation in vivo, suggesting that the Akt/MDM2/p53 pathway is responsible for suppression of apoptosis. Dominant-negative Akt blocked phosphorylation of MDM2 in salivary acinar cells from myr-Akt1 transgenic mice. Reduction of MDM2 levels in myr-Akt1 primary salivary acinar cells with small interfering RNA increases the levels of p53 protein and renders these cells susceptible to etoposide-induced apoptosis in spite of the presence of activated Akt1. These results indicate that MDM2 is a critical substrate of activated Akt1 in the suppression of p53-dependent apoptosis in vivo.
Collapse
Affiliation(s)
- Kirsten H Limesand
- Department of Pathology, University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO 80045, USA
| | | | | |
Collapse
|
285
|
Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE, Sewing S, Treinies I, Zitzer H, Gromada J. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006; 55:2470-8. [PMID: 16936195 DOI: 10.2337/db05-1435] [Citation(s) in RCA: 378] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Fibroblast growth factor-21 (FGF-21) is a recently discovered metabolic regulator. Here, we investigated the effects of FGF-21 in the pancreatic beta-cell. In rat islets and INS-1E cells, FGF-21 activated extracellular signal-regulated kinase 1/2 and Akt signaling pathways. In islets isolated from healthy rats, FGF-21 increased insulin mRNA and protein levels but did not potentiate glucose-induced insulin secretion. Islets and INS-1E cells treated with FGF-21 were partially protected from glucolipotoxicity and cytokine-induced apoptosis. In islets isolated from diabetic rodents, FGF-21 treatment increased islet insulin content and glucose-induced insulin secretion. Short-term treatment of normal or db/db mice with FGF-21 lowered plasma levels of insulin and improved glucose clearance compared with vehicle after oral glucose tolerance testing. Constant infusion of FGF-21 for 8 weeks in db/db mice nearly normalized fed blood glucose levels and increased plasma insulin levels. Immunohistochemistry of pancreata from db/db mice showed a substantial increase in the intensity of insulin staining in islets from FGF-21-treated animals as well as a higher number of islets per pancreas section and of insulin-positive cells per islet compared with control. No effect of FGF-21 was observed on islet cell proliferation. In conclusion, preservation of beta-cell function and survival by FGF-21 may contribute to the beneficial effects of this protein on glucose homeostasis observed in diabetic animals.
Collapse
Affiliation(s)
- Wolf Wente
- Lilly Research Laboratories, Essener Bogen 7, D-22419 Hamburg, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
286
|
Dummler B, Tschopp O, Hynx D, Yang ZZ, Dirnhofer S, Hemmings BA. Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol Cell Biol 2006; 26:8042-51. [PMID: 16923958 PMCID: PMC1636753 DOI: 10.1128/mcb.00722-06] [Citation(s) in RCA: 196] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
To address the issues of isoform redundancy and isoform specificity of the Akt family of protein kinases in vivo, we generated mice deficient in both Akt2 and Akt3. In these mice, only the Akt1 isoform remains to perform essential Akt functions, such as glucose homeostasis, proliferation, differentiation, and early development. Surprisingly, we found that Akt2(-/-) Akt3(-/-) and even Akt1(+/-) Akt2(-/-) Akt3(-/-) mice developed normally and survived with minimal dysfunctions, despite a dramatic reduction of total Akt levels in all tissues. A single functional allele of Akt1 appears to be sufficient for successful embryonic development and postnatal survival. This is in sharp contrast to the previously described lethal phenotypes of Akt1(-/-) Akt2(-/-) mice and Akt1(-/-) Akt3(-/-) mice. However, Akt2(-/-) Akt3(-/-) mice were glucose and insulin intolerant and exhibited an approximately 25% reduction in body weight compared to wild-type mice. In addition, we found substantial reductions in relative size and weight of the brain and testis in Akt2(-/-) Akt3(-/-) mice, demonstrating an in vivo role for both Akt2 and Akt3 in the determination of whole animal size and individual organ sizes.
Collapse
Affiliation(s)
- Bettina Dummler
- Friedrich Miescher Institute for Biomedical Research, Basel CH-4058, Switzerland
| | | | | | | | | | | |
Collapse
|
287
|
Hussain MA, Porras DL, Rowe MH, West JR, Song WJ, Schreiber WE, Wondisford FE. Increased pancreatic beta-cell proliferation mediated by CREB binding protein gene activation. Mol Cell Biol 2006; 26:7747-59. [PMID: 16908541 PMCID: PMC1636850 DOI: 10.1128/mcb.02353-05] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The cyclic AMP (cAMP) signaling pathway is central in beta-cell gene expression and function. In the nucleus, protein kinase A (PKA) phosphorylates CREB, resulting in recruitment of the transcriptional coactivators p300 and CREB binding protein (CBP). CBP, but not p300, is phosphorylated at serine 436 in response to insulin action. CBP phosphorylation disrupts CREB-CBP interaction and thus reduces nuclear cAMP action. To elucidate the importance of the cAMP-PKA-CREB-CBP pathway in pancreatic beta cells specifically at the nuclear level, we have examined mutant mice lacking the insulin-dependent phosphorylation site of CBP. In these mice, the CREB-CBP interaction is enhanced in both the absence and presence of cAMP stimulation. We found that islet and beta-cell masses were increased twofold, while pancreas weights were not different from the weights of wild-type littermates. beta-Cell proliferation was increased both in vivo and in vitro in isolated islet cultures. Surprisingly, glucose-stimulated insulin secretion from perfused, isolated mutant islets was reduced. However, beta-cell depolarization with KCl induced similar levels of insulin release from mutant and wild-type islets, indicating normal insulin synthesis and storage. In addition, transcripts of pgc1a, which disrupts glucose-stimulated insulin secretion, were also markedly elevated. In conclusion, sustained activation of CBP-responsive genes results in increased beta-cell proliferation. In these beta cells, however, glucose-stimulated insulin secretion was diminished, resulting from concomitant CREB-CBP-mediated pgc1a gene activation.
Collapse
Affiliation(s)
- Mehboob A Hussain
- Metabolism Division, Department of Pediatrics and Medicine, Johns Hopkins University, 600 N. Wolfe Street, CMSC 10-113, Baltimore, MD 21287, USA.
| | | | | | | | | | | | | |
Collapse
|
288
|
Nguyen KTT, Tajmir P, Lin CH, Liadis N, Zhu XD, Eweida M, Tolasa-Karaman G, Cai F, Wang R, Kitamura T, Belsham DD, Wheeler MB, Suzuki A, Mak TW, Woo M. Essential role of Pten in body size determination and pancreatic beta-cell homeostasis in vivo. Mol Cell Biol 2006; 26:4511-8. [PMID: 16738317 PMCID: PMC1489140 DOI: 10.1128/mcb.00238-06] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
PTEN (phosphatase with tensin homology) is a potent negative regulator of phosphoinositide 3-kinase (PI3K)/Akt signaling, an evolutionarily conserved pathway that signals downstream of growth factors, including insulin and insulin-like growth factor 1. In lower organisms, this pathway participates in fuel metabolism and body size regulation and insulin-like proteins are produced primarily by neuronal structures, whereas in mammals, the major source of insulin is the pancreatic beta cells. Recently, rodent insulin transcription was also shown in the brain, particularly the hypothalamus. The specific regulatory elements of the PI3K pathway in these insulin-expressing tissues that contribute to growth and metabolism in higher organisms are unknown. Here, we report PTEN as a critical determinant of body size and glucose metabolism when targeting is driven by the rat insulin promoter in mice. The partial deletion of PTEN in the hypothalamus resulted in significant whole-body growth restriction and increased insulin sensitivity. Efficient PTEN deletion in beta cells led to increased islet mass without compromise of beta-cell function. Parallel enhancement in PI3K signaling was found in PTEN-deficient hypothalamus and beta cells. Together, we have shown that PTEN in insulin-transcribing cells may play an integrative role in regulating growth and metabolism in vivo.
Collapse
Affiliation(s)
- Kinh-Tung T Nguyen
- Department of Medicine, Medical Biophysics, Institute of Medical Science, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
289
|
Li LX, MacDonald PE, Ahn DS, Oudit GY, Backx PH, Brubaker PL. Role of phosphatidylinositol 3-kinasegamma in the beta-cell: interactions with glucagon-like peptide-1. Endocrinology 2006; 147:3318-25. [PMID: 16574789 DOI: 10.1210/en.2006-0155] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Glucagon-like peptide-1 (GLP-1) increases beta-cell function and growth through protein kinase A- and phosphatidylinositol-3-kinase (PI3-K)/protein kinase B, respectively. GLP-1 acts via a G protein-coupled receptor, and PI3-Kgamma is known to be activated by G(betagamma.) Therefore, the role of PI3-Kgamma in the chronic effects of GLP-1 on the beta-cell was investigated using PI3-Kgamma knockout (KO) mice treated with the GLP-1 receptor agonist, exendin-4 (Ex4; 1 nmol/kg sc every 24 h for 14 d). In vivo, glucose and insulin responses were similar in PBS- and Ex4-treated KO and wild-type (WT) mice. However, glucose-stimulated insulin secretion was markedly impaired in islets from PBS-KO mice (P < 0.05), and this was partially normalized by chronic Ex4 treatment (P < 0.05). In contrast, insulin content was increased in PBS-KO islets, and this was paradoxically decreased by Ex4 treatment, compared with the stimulatory effect of Ex4 on WT islets (P < 0.05-0.01). Transfection of INS-1E beta-cells with small interfering RNA for PI3-Kgamma similarly decreased glucose-stimulated insulin secretion (P < 0.01) and increased insulin content. Basal values for beta-cell mass, islet number and proliferation, glucose transporter 2, glucokinase, and insulin receptor substrate-2 were increased in PBS-KO mice (P < 0.05-0.001) and, although they were increased by Ex4 treatment of WT animals (P < 0.05), they were decreased in Ex4-KO mice (P < 0.05-0.01). These findings indicate that PI3-Kgamma deficiency impairs insulin secretion, resulting in compensatory islet growth to maintain normoglycemia. Chronic Ex4 treatment normalizes the secretory defect, thereby relieving the pressure for expansion of beta-cell mass. These studies reveal a new role for PI3-Kgamma as a positive regulator of insulin secretion, and reinforce the importance of GLP-1 for the maintenance of normal beta-cell function.
Collapse
Affiliation(s)
- Li-Xin Li
- Department of Physiology, University of Toronto, Toronto, Ontario, Canada M5S 1A8
| | | | | | | | | | | |
Collapse
|
290
|
Martinez SC, Cras-Méneur C, Bernal-Mizrachi E, Permutt MA. Glucose regulates Foxo1 through insulin receptor signaling in the pancreatic islet beta-cell. Diabetes 2006; 55:1581-91. [PMID: 16731820 DOI: 10.2337/db05-0678] [Citation(s) in RCA: 98] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Glucose controls islet beta-cell mass and function at least in part through the phosphatidylinositol 3-kinase (PI3K)/Akt pathway downstream of insulin signaling. The Foxo proteins, transcription factors known in other tissues to be negatively regulated by Akt activation, affect proliferation and metabolism. In this study, we tested the hypothesis that glucose regulates Foxo1 activity in the beta-cell via an autocrine/paracrine effect of released insulin on its receptor. Mouse insulinoma cells (MIN6) were starved overnight for glucose (5 mmol/l) then refed with glucose (25 mmol/l), resulting in rapid Foxo1 phosphorylation (30 min, P < 0.05 vs. untreated). This glucose response was demonstrated to be time (0.5-2 h) and dose (5-30 mmol/l) dependent. The use of inhibitors demonstrated that glucose-induced Foxo1 phosphorylation was dependent upon depolarization, calcium influx, and PI3K signaling. Additionally, increases in glucose concentration over a physiological range (2.5-20 mmol/l) resulted in nuclear to cytoplasmic translocation of Foxo1. Phosphorylation and translocation of Foxo1 following glucose refeeding were eliminated in an insulin receptor knockdown cell line, indicating that the glucose effects are mediated primarily through the insulin receptor. Activity of Foxo1 was observed to increase with decreased glucose concentrations, assessed by an IGF binding protein-1 promoter luciferase assay. Starvation of MIN6 cells identified a putative Foxo1 target, Chop, and a Chop-promoter luciferase assay in the presence of cotransfected Foxo1 supported this hypothesis. The importance of these observations was that nutritional alterations in the beta-cell are associated with changes in Foxo1 transcriptional activity and that these changes are predominantly mediated through glucose-stimulated insulin secretion acting through its own receptor.
Collapse
Affiliation(s)
- Sara C Martinez
- Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8127, St. Louis, MO 63110, USA
| | | | | | | |
Collapse
|
291
|
Chen S, Ding JH, Bekeredjian R, Yang BZ, Shohet RV, Johnston SA, Hohmeier HE, Newgard CB, Grayburn PA. Efficient gene delivery to pancreatic islets with ultrasonic microbubble destruction technology. Proc Natl Acad Sci U S A 2006; 103:8469-74. [PMID: 16709667 PMCID: PMC1482516 DOI: 10.1073/pnas.0602921103] [Citation(s) in RCA: 161] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2005] [Indexed: 12/31/2022] Open
Abstract
This study describes a method of gene delivery to pancreatic islets of adult, living animals by ultrasound targeted microbubble destruction (UTMD). The technique involves incorporation of plasmids into the phospholipid shell of gas-filled microbubbles, which are then infused into rats and destroyed within the pancreatic microcirculation with ultrasound. Specific delivery of genes to islet beta cells by UTMD was achieved by using a plasmid containing a rat insulin 1 promoter (RIP), and reporter gene expression was regulated appropriately by glucose in animals that received a RIP-luciferase plasmid. To demonstrate biological efficacy, we used UTMD to deliver RIP-human insulin and RIP-hexokinase I plasmids to islets of adult rats. Delivery of the former plasmid resulted in clear increases in circulating human C-peptide and decreased blood glucose levels, whereas delivery of the latter plasmid resulted in a clear increase in hexokinase I protein expression in islets, increased insulin levels in blood, and decreased circulating glucose levels. We conclude that UTMD allows relatively noninvasive delivery of genes to pancreatic islets with an efficiency sufficient to modulate beta cell function in adult animals.
Collapse
Affiliation(s)
- Shuyuan Chen
- *Department of Internal Medicine, Cardiology Section, Baylor University Medical Center, Baylor Heart and Vascular Institute, 621 North Hall Street, Suite H030, Dallas, TX 75226
- Institute of Metabolic Disease, Baylor University Medical Center, Dallas, TX 75246
| | - Jia-huan Ding
- Institute of Metabolic Disease, Baylor University Medical Center, Dallas, TX 75246
| | | | - Bing-zhi Yang
- Institute of Metabolic Disease, Baylor University Medical Center, Dallas, TX 75246
| | - Ralph V. Shohet
- Department of Internal Medicine, Division of Cardiology, and
| | - Stephen A. Johnston
- Center for Biomedical Invention, University of Texas Southwestern Medical Center, Dallas, TX 75390; and
| | - Hans E. Hohmeier
- Sarah W. Stedman Nutrition and Metabolism Center, Departments of Pharmacology and Cancer Biology and Medicine, Duke University Medical Center, Durham, NC 27710
| | - Christopher B. Newgard
- Sarah W. Stedman Nutrition and Metabolism Center, Departments of Pharmacology and Cancer Biology and Medicine, Duke University Medical Center, Durham, NC 27710
| | - Paul A. Grayburn
- *Department of Internal Medicine, Cardiology Section, Baylor University Medical Center, Baylor Heart and Vascular Institute, 621 North Hall Street, Suite H030, Dallas, TX 75226
| |
Collapse
|
292
|
Elghazi L, Balcazar N, Bernal-Mizrachi E. Emerging role of protein kinase B/Akt signaling in pancreatic β-cell mass and function. Int J Biochem Cell Biol 2006. [DOI: 10.1016/j.biocel.2006.01.005] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
293
|
Stiles BL, Kuralwalla-Martinez C, Guo W, Gregorian C, Wang Y, Tian J, Magnuson MA, Wu H. Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes. Mol Cell Biol 2006; 26:2772-81. [PMID: 16537919 PMCID: PMC1430339 DOI: 10.1128/mcb.26.7.2772-2781.2006] [Citation(s) in RCA: 111] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a lipid phosphatase. PTEN inhibits the action of phosphatidylinositol-3-kinase and reduces the levels of phosphatidylinositol triphosphate, a crucial second messenger for cell proliferation and survival, as well as insulin signaling. In this study, we deleted Pten specifically in the insulin producing beta cells during murine pancreatic development. Pten deletion leads to increased cell proliferation and decreased cell death, without significant alteration of beta-cell differentiation. Consequently, the mutant pancreas generates more and larger islets, with a significant increase in total beta-cell mass. PTEN loss also protects animals from developing streptozotocin-induced diabetes. Our data demonstrate that PTEN loss in beta cells is not tumorigenic but beneficial. This suggests that modulating the PTEN-controlled signaling pathway is a potential approach for beta-cell protection and regeneration therapies.
Collapse
Affiliation(s)
- Bangyan L Stiles
- Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California 90095, USA
| | | | | | | | | | | | | | | |
Collapse
|
294
|
Abstract
The proper regulation of blood glucose homeostasis in mammals requires an adequate relation between the capacity to produce insulin and metabolic demand. Insulin receptor substrate proteins (IRS) are signalling intermediates that are required to keep this balance because they are needed for insulin action in target tissues but also for insulin production in pancreatic beta-cells. The total functional beta-cell mass in an individual sets the limit of how much insulin can be produced at a given time. It can change adaptively to meet demand and studies in vivo indicate that the regulation of beta-cell mass involves IRS2, while IRS1 is only required for proper insulin production in beta-cells. Overexpression studies in isolated islets have shown that IRS2, but not IRS1 or Shc, is sufficient to induce proliferation of beta-cells and to protect against d-glucose-induced apoptosis. In light of the finding that many growth factors can regulate Irs2 in islets, this signalling intermediate could balance capacity for insulin production with demand. This review summarizes observations in mouse models and in primary beta-cells and proposes a new hypothetical model of how IRS2 might control beta-cell mass.
Collapse
Affiliation(s)
- Markus Niessen
- Clinic of Endocrinology and Diabetes, University Hospital Zurich, Zurich, Switzerland.
| |
Collapse
|
295
|
Lingohr MK, Briaud I, Dickson LM, McCuaig JF, Alárcon C, Wicksteed BL, Rhodes CJ. Specific regulation of IRS-2 expression by glucose in rat primary pancreatic islet beta-cells. J Biol Chem 2006; 281:15884-92. [PMID: 16574657 DOI: 10.1074/jbc.m600356200] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Insulin receptor substrate 2 (IRS-2) plays a critical role in pancreatic beta-cells. Increased IRS-2 expression promotes beta-cell growth and survival, whereas decreased IRS-2 levels lead to apoptosis. It was found that IRS-2 turnover in rat islet beta-cells was rapid, with mRNA and protein half-lives of approximately 90 min and approximately 2 h, respectively. However, this was countered by specific glucose-regulated IRS-2 expression mediated at the transcriptional level. Glucose (> or = 6 mM) increased IRS-2 mRNA and protein levels in a dose-dependent manner, reaching a maximum 4-fold increase in IRS-2 mRNA and a 5-6-fold increase in IRS-2 protein levels at > or = 12 mM glucose (p < or = 0.01). Glucose (15 mM) regulation of islet beta-cell IRS-2 gene expression was rapid, with a significant increase in IRS-2 mRNA levels within 2 h that reached a maximum 4-fold increase by 4 h. IRS-2 protein expression in beta-cells followed that of IRS-2 mRNA. Glucose metabolism was necessary for increased IRS-2 expression in beta-cells. Moreover, inhibition of a glucose-induced rise in islet beta-cell cytosolic [Ca2+]i prevented an increase in IRS-2 expression, indicating this was Ca2+-dependent. The glucose-induced rise in IRS-2 levels correlated with increased IRS-2 tyrosine phosphorylation and downstream activation of protein kinase B. These data indicate that fluctuations of glucose in the normal physiological range (5-15 mM) promote beta-cell survival via regulation of IRS-2 expression and a subsequent parallel protein kinase B activation. Given that the onset of type-2 diabetes is marked by loss of beta-cells, these data further the idea that controlled IRS-2 expression in beta-cells could be a therapeutic means to promote beta-cell survival and delay the onset of the disease.
Collapse
Affiliation(s)
- Melissa K Lingohr
- The Pacific Northwest Research Institute, Seattle, Washington 98122, USA
| | | | | | | | | | | | | |
Collapse
|
296
|
Verga Falzacappa C, Panacchia L, Bucci B, Stigliano A, Cavallo MG, Brunetti E, Toscano V, Misiti S. 3,5,3'-triiodothyronine (T3) is a survival factor for pancreatic beta-cells undergoing apoptosis. J Cell Physiol 2006; 206:309-21. [PMID: 16021636 DOI: 10.1002/jcp.20460] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
3,5,3'-triiodothyronine (T3) is essential for the growth and the regulation of metabolic functions, moreover, the growth-stimulatory effect of T3 has largely been demonstrated and the pathways via which T3 promotes cell growth have been recently investigated. Type 1 diabetes (T1D) is due to the destruction of beta-cells, which occurs even through apoptosis. Aim of our study was to analyze whether T3 could have an antiapoptotic effect on cultured beta-cells undergoing apoptosis. We have demonstrated that T3 promotes cell proliferation in islet beta-cell lines (rRINm5F and hCM) provoking an increment in cell number (up to 55%: rRINm5F and 45%: hCM), cell viability, and BrdU incorporation, and regulating the cell cycle-related molecules (cyc A, D1, E, and p27(kip1)). T3 inhibited the apoptotic process induced by streptozocin, S-Nitroso-N-Acetylpenicylamine (SNAP), and H2O2 via regulation of the pro- and anti-apoptotic factors Bcl-2, Bcl-XL, Bad, Bax, and Caspase 3. The T3 protective effect was PI-3 K-, but not MAPK- or PKA-mediated, involving pAktThr308. Thus, T3 could be considered a survival factor protecting islet beta-cells from apoptosis.
Collapse
|
297
|
Higa M, Shimabukuro M, Shimajiri Y, Takasu N, Shinjyo T, Inaba T. Protein kinase B/Akt signalling is required for palmitate-induced beta-cell lipotoxicity. Diabetes Obes Metab 2006; 8:228-33. [PMID: 16448528 DOI: 10.1111/j.1463-1326.2005.00488.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
AIM This study was conducted to clarify cell death and survival signals in pancreatic beta-cell lipotoxicity. METHODS Rat insulinoma INS-1 cells, with or without expression of dominant-negative mutant of Akt (K179M), were cultured with palmitate (C16:0) or oleate (C18:1) and cell numbers were determined by 0.2% eosin dye exclusion assay. The Akt activity was determined by anti-3'-phospho-inositide-dependent protein kinase (Akt)/protein kinase B (PKB) or anti-phospho-Akt (Serine 473) immunoblotting, and nuclear protein nuclear factor-kB (NF-kappaB)-binding activity was by supershift analysis. RESULTS Twenty-four hours treatment with palmitate increased the INS-1 cell number at 0.1-0.2 mM but decreased the cell number at 0.5-1 mM. Oleate did not affect cell number at 0.1-1.0 mM. Palmitate dose-dependently increased phosphorylation of 473th serine in Akt/PKB. The K179M form of Akt/PKB abolished palmitate-induced cell proliferation at the low dose and death at the high dose. Nuclear protein NF-kappaB binding was enhanced at 0.2 and 0.5 mM of palmitate but decreased at 1.0 mM. CONCLUSION Results suggest that Akt/PKB signalling is involved in palmitate-induced cell death and survival of pancreatic beta cell.
Collapse
Affiliation(s)
- M Higa
- Second Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan
| | | | | | | | | | | |
Collapse
|
298
|
Zhang N, Kumar M, Xu G, Ju W, Yoon T, Xu E, Huang X, Gaisano H, Peng C, Wang Q. Activin receptor-like kinase 7 induces apoptosis of pancreatic beta cells and beta cell lines. Diabetologia 2006; 49:506-18. [PMID: 16440210 DOI: 10.1007/s00125-005-0095-1] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2005] [Accepted: 10/06/2005] [Indexed: 12/14/2022]
Abstract
AIMS/HYPOTHESIS Activin receptor-like kinase 7 (ALK7), a member of the type I receptor serine/threonine kinases of the TGF-beta superfamily, was recently reported to regulate cell proliferation and apoptosis. We hypothesised that ALK7 may play a role in modulating pancreatic beta cell proliferation and/or apoptosis. METHODS We detected ALK7 expression in beta cells using RT-PCR, immunostaining and western blotting. Constitutively active, dominant negative or wild-type ALK7 was introduced into beta cells using adenoviral delivery. Proliferation was assessed using (3)H-thymidine incorporation and apoptosis was quantified using terminal deoxynucleotidyl transferase biotin-dUTP nick end labelling detection, DNA degradation analysis and caspase-3 assays. RESULTS Induction of constitutively active ALK7 in beta cells resulted in growth inhibition and enhanced apoptosis; no effect was seen with INS-1 cells expressing wild-type or dominant negative ALK7. Elevated glucose concentrations and fatty acid (palmitate) markedly increased expression levels of ALK7 transcripts and proteins in INS-1 and rat islets and increased beta cell apoptosis. Activation of ALK7 increased Smad2 phosphorylation, reduced protein kinase B (Akt) kinase activity and was associated with increased levels of the bioactive forms of caspase-3, whereas co-expression of constitutively active ALK7 with dominant negative Smad2 or constitutively active Akt significantly diminished ALK7-induced growth inhibition and apoptosis in INS-1 cells. Although overexpression of constitutively active Akt significantly reduced ALK7-induced growth inhibition and ALK7-enhanced beta cell apoptosis, ALK7-stimulated Smad2 phosphorylation was not affected. CONCLUSIONS/INTERPRETATION These results suggest that the pancreatic beta cell apoptosis induced by ALK7 activation occurs via the activation of two distinct downstream pathways: the suppression of Akt activation and the activation of the Smad2-caspase-3 cascade.
Collapse
Affiliation(s)
- N Zhang
- Division of Endocrinology and Metabolism, St Michael's Hospital, 30 Bond Street, Room 7005, M5B 1W8 Toronto, ON, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
299
|
Wobser H, Bonner C, Nolan JJ, Byrne MM, Prehn JHM. Downregulation of protein kinase B/Akt-1 mediates INS-1 insulinoma cell apoptosis induced by dominant-negative suppression of hepatocyte nuclear factor-1alpha function. Diabetologia 2006; 49:519-26. [PMID: 16440211 DOI: 10.1007/s00125-005-0119-x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2005] [Accepted: 10/10/2005] [Indexed: 12/31/2022]
Abstract
AIMS/HYPOTHESIS Inactivating mutations in Tcf1, which encodes the transcription factor hepatocyte nuclear factor (HNF)-1alpha, cause maturity-onset diabetes of the young-3. We have previously shown that a dominant-negative mutant (DN-HNF-1alpha) renders INS-1 insulinoma cells sensitive to the mitochondrial apoptosis pathway, but the underlying alterations in signal transduction remain unknown. MATERIALS AND METHODS Using a reverse tetracycline-dependent transactivator system, DN-HNF-1alpha-induced apoptosis was assessed by immunoblotting and caspase assays. Alterations in AKT1 kinase/protein kinase B (AKT1) survival signalling during DN-HNF-1alpha-induced apoptosis were investigated by phospho-specific immunodetection and transient transfection experiments. RESULTS Induction of DN-HNF-1alpha caused significant changes in the activation-specific phosphorylation status of AKT1 that were preceded by a downregulation of Ins1 gene transcription. Phosphorylation of AKT1 at Ser473 was dramatically reduced after 36 to 48 h of DN-HNF-1alpha induction and coincided with maximal apoptosis activation. Overexpression of a constitutively active mutant of Akt1 rescued INS-1 cells from DN-HNF-1alpha-induced apoptosis, while ectopic expression of a dominant-negative mutant mimicked the effect of DN-HNF-1alpha on apoptosis activation. Pharmacological suppression of growth factor survival signalling through administration of the phosphatidylinositol-3 kinase (PI-3K) inhibitor wortmannin accelerated the induction of apoptosis by DN-HNF-1alpha. CONCLUSIONS/INTERPRETATION These data suggest that a decrease in PI-3K/AKT1 survival signalling mediates DN-HNF-1alpha-induced apoptosis in insulin-secreting cells.
Collapse
Affiliation(s)
- H Wobser
- Department of Physiology, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland
| | | | | | | | | |
Collapse
|
300
|
Okamoto H, Hribal ML, Lin HV, Bennett WR, Ward A, Accili D. Role of the forkhead protein FoxO1 in beta cell compensation to insulin resistance. J Clin Invest 2006; 116:775-82. [PMID: 16485043 PMCID: PMC1370178 DOI: 10.1172/jci24967] [Citation(s) in RCA: 97] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2005] [Accepted: 12/22/2005] [Indexed: 12/31/2022] Open
Abstract
Diabetes is associated with defective beta cell function and altered beta cell mass. The mechanisms regulating beta cell mass and its adaptation to insulin resistance are unknown. It is unclear whether compensatory beta cell hyperplasia is achieved via proliferation of existing beta cells or neogenesis from progenitor cells embedded in duct epithelia. We have used transgenic mice expressing a mutant form of the forkhead-O1 transcription factor (FoxO1) in both pancreatic ductal and endocrine beta cells to assess the contribution of these 2 compartments to islet expansion. We show that the mutant FoxO1 transgene prevents beta cell replication in 2 models of beta cell hyperplasia, 1 due to peripheral insulin resistance (Insulin receptor transgenic knockouts) and 1 due to ectopic local expression of IGF2 (Elastase-IGF2 transgenics), without affecting insulin secretion. In contrast, we failed to detect a specific effect of the FoxO1 transgene on the number of periductal beta cells. We propose that beta cell compensation to insulin resistance is a proliferative response of existing beta cells to growth factor signaling and requires FoxO1 nuclear exclusion.
Collapse
Affiliation(s)
- Haruka Okamoto
- Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York, USA
| | | | | | | | | | | |
Collapse
|